Nyrada
Menu
NYR:
Market Cap*:
Price Delay ~20min
Home
About Us
Company Overview
Board of Directors
Senior Management
Scientific Advisory Board
Corporate Governance
Programs
Xolatryp
Myocardial Ischemia and Arrhythmia Control
Stroke
Traumatic Brain Injury
Investors
Investor Welcome
Company Fact Sheet
ASX Announcements
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past General Meetings
News & Insights
Presentations & Interviews
Media
Newsletters
Publications
Contact Us
Contact Us
Working at Nyrada
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Welcome
Company Fact Sheet
ASX Announcements
Financial Reports
Corporate Announcements
Investor Presentations
Share Price Information
Investors Glossary
Annual Reports
Analyst Reports
Annual General Meeting
Extraordinary General Meeting
Past General Meetings
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
13-Jun-2025
Notification of cessation of securities - NYR
12-Jun-2025
Notice of Change of Interests of Substantial Holder - M Azzi
5-Jun-2025
Notice of Change of Interests of Substantial Holder - M Azzi
4-Jun-2025
Phase I Clinical Trial Protocol Amendment
3-Jun-2025
Notice of Change of Interests of Substantial Holder - M Azzi
28-May-2025
Notice of Change of Interests of Substantial Holder - M Azzi
26-May-2025
Notice of Change of Interests of Substantial Holder - M Azzi
23-May-2025
Lead Drug Candidate Renamed to Xolatryp
21-May-2025
Notice of Change of Interests of Substantial Holder - M Azzi
21-May-2025
Phase I Clinical Trial Dosing Update No 3
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
Next
